Rapid communication

Opioid δ receptor subtypes are associated with different potassium channels

Kenneth D. Wild, Todd Vanderah, Henry I. Mosberg 1 and Frank Porreca

Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, AZ 85724, U.S.A. and 1 College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, U.S.A.

Received 31 December 1990, accepted 2 January 1991

Previous data have indicated that opioid μ and δ receptors may act by opening potassium channels in the central nervous system (North, 1986). A recent report by Ocana et al. (1990) suggests that morphine antinociception may be associated with ATP-sensitive potassium channels. This conclusion was based on the finding that the antinociceptive effect of morphine was antagonized by glybenclamide, a compound which blocks ATP-sensitive potassium channels (Amoroso et al., 1990), but not by tetraethylammonium bromide (TEA), a compound thought to act on other types of potassium channels (Cook, 1988). This finding raised the question of whether opioid δ receptors are linked with the same potassium channels as morphine, and whether subtypes of opioid δ receptors are linked to the same potassium channels. Evidence suggesting the existence of opioid δ receptor subtypes has now been accumulated, and has demonstrated that these receptors are activated selectively by [D-Pen2,D-Pen5]enkephalin (DPDPE) or by [D-Ala2]deltorphin II (Jiang et al., 1990; Jiang, Mosberg and Porreca, submitted). The purpose of the present experiment was to determine (a) whether the antinociceptive actions of DPDPE could also be linked to a glybenclamide-sensitive potassium channel (presumably an ATP-sensitive potassium channel) and (b) whether the antinociceptive actions of [D-Ala2]deltorphin II were associated with potassium channels and if so, whether these channels were also of the glybenclamide-sensitive type. Additionally, in order to validate the data, an opioid κ receptor agonist was tested as this receptor is thought to be linked to calcium channels in the central nervous system (North, 1986) and responses mediated through this receptor type should be insensitive to potassium channel blockers.

Male, ICR mice (25-30 g, Harlan) were used. Antinociception was determined by recording the latency to a rapid tail-flick using warm water (55°C) as the nociceptive stimulus with a cut-off time of 15 s. Mice received graded intracerebroventricular (i.c.v.) injections of distilled water or vehicle (0.1% DMSO for [D-Ala2]deltorphin II only and 2.5% Tween 80 for glybenclamide only), morphine sulfate (Mallinckrodt), DPDPE, [D-Ala2]deltorphin II or U69,593 (Sigma) alone, glybenclamide (40 μg) or TEA (40 μg) alone, or co-administered agonist with glybenclamide (40 μg) or TEA (40 μg). All compounds were administered in a volume of 5 μl; DPDPE and [D-Ala2]deltorphin II were synthesized as previously reported. Antinociception was calculated 10 min after i.c.v. injection using the following formula: % antinociception = 100 × (test latency - control latency)/(15 - control latency).

The data from these experiments are shown in table 1. Neither glybenclamide, TEA or any vehicle produced any measurable antinociception alone (data not shown). In agreement with the results of Ocana et al. (1990), the antinociceptive effects of morphine were antagonized by glybenclamide, but not by TEA. Similarly, the antinociceptive actions of DPDPE were blocked by glybenclamide, but not by TEA. As expected, the antinociceptive effects of the κ agonist, U69,593 were insensitive to both glybenclamide and to TEA. In contrast to the results with morphine and with DPDPE, however, the antinociceptive actions of [D-Ala2]deltorphin II were blocked by TEA, but not by glybenclamide.

The present results confirm the previous suggestions that morphine antinociception is sensitive to glybenclamide, implicating ATP-sensitive potassium channels in this effect. Additionally, these data show that the antinociception produced by the opioid δ agonist, DPDPE, is also sensitive to glybenclamide, implying that this type of δ receptor is also linked to an ATP-sensitive potassium channel. In contrast to this result, however, the data indicate that the effects of another highly selective δ agonist, [D-Ala2]deltorphin II (Jiang et al., 1990), are mediated through a glybenclamide-insensitive potassium channel. That this δ receptor subtype is also linked to potassium channels is supported.
TABLE 1
Antinociceptive A50 values (and 95% confidence intervals) for agonists acting at opioid receptor subtypes in the mouse tail-flick test.

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Glybenclamide (GLYB)</th>
<th>Tetraethylammonium (TEA)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alone + 40 µg Glyb</td>
<td>Shift ratio</td>
</tr>
<tr>
<td>Morphine</td>
<td>1.462 (0.81-2.11)</td>
<td>7.18 (3.77-10.59)</td>
</tr>
<tr>
<td>DPDPE</td>
<td>21.319 (15.52-27.12)</td>
<td>192.93 (9.94-375.91)</td>
</tr>
<tr>
<td>Deltorphin II</td>
<td>12.235 (9.11-15.36)</td>
<td>10.664 (8.30-13.03)</td>
</tr>
<tr>
<td>U69,593</td>
<td>25.477 (17.68-33.28)</td>
<td>26.60 (17.35-35.85)</td>
</tr>
</tbody>
</table>

by the sensitivity of the antinociceptive effect of TEA. Given the previous evidence linking θ receptors to calcium channels, the lack of effect of either glybenclamide or TEA is not surprising and confirms the validity of the present approach. Thus, it appears that δ receptor subtypes may be linked to different types of potassium channels which can be discriminated on the basis of sensitivity to glybenclamide or TEA. These glybenclamide-sensitive potassium channels (i.e., presumably ATP-sensitive potassium channels) appear to be activated by µ opioids such as morphine as well as by the classical δ agonist, DPDPE. Additionally, the present study reveals that a δ receptor subtype, selectively acted upon by [D-Ala2]deltorphin II, produces an antinociceptive effect via TEA-sensitive potassium channels. The data confirm the existence of δ receptor subtypes and offer novel insights into the mechanism by which these receptors may mediate their antinociceptive effects.

Acknowledgements

This work was supported by USPHS Grants DA 04285, DA 06284 and DA 03910 from the National Institute on Drug Abuse. H.I.M. is the recipient of a Research Scientist Development Award from the National Institute on Drug Abuse (DA 00118).

References